U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Substance Class Protein
Created
by admin
on Sat Dec 16 12:23:00 GMT 2023
Edited
by admin
on Sat Dec 16 12:23:00 GMT 2023
Protein Sub Type
Sequence Type COMPLETE
Record UNII
7J9Y28299R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2
Common Name English
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
Common Name English
CD340
Common Name English
NEU
Common Name English
METASTATIC LYMPH NODE GENE 19 PROTEIN
Common Name English
NGL
Common Name English
TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER2
Common Name English
PROTO-ONCOGENE NEU
Common Name English
HER2/NEU
Common Name English
ERBB2
Common Name English
P185ERBB2
Common Name English
HER-2
Common Name English
HER2
Common Name English
PROTO-ONCOGENE C-ERBB-2
Common Name English
MLN19
Common Name English
ERBB-2
Common Name English
Code System Code Type Description
FDA UNII
7J9Y28299R
Created by admin on Sat Dec 16 12:23:02 GMT 2023 , Edited by admin on Sat Dec 16 12:23:02 GMT 2023
PRIMARY
WIKIPEDIA
HER2/neu
Created by admin on Sat Dec 16 12:23:02 GMT 2023 , Edited by admin on Sat Dec 16 12:23:02 GMT 2023
PRIMARY
UNIPROT
P04626
Created by admin on Sat Dec 16 12:23:02 GMT 2023 , Edited by admin on Sat Dec 16 12:23:02 GMT 2023
PRIMARY
From To
1_4 1_31
1_140 1_170
1_173 1_182
1_177 1_190
1_198 1_205
1_202 1_213
1_214 1_222
1_218 1_230
1_233 1_242
1_246 1_273
1_277 1_289
1_293 1_309
1_312 1_316
1_320 1_345
1_453 1_482
1_489 1_498
1_493 1_506
1_509 1_518
1_522 1_538
1_541 1_554
1_545 1_562
1_565 1_574
1_578 1_601
1_604 1_612
1_608 1_620
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_46
N 1_102
N 1_165
N 1_237
N 1_508
N 1_549
N 1_607
Related Record Type Details
Structure of 4,6-QUINAZOLINEDIAMINE, N4-(3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)-
WEAK INHIBITOR->TARGET
IC50
Structure of 2-PROPENAMIDE, N-(4-((3-CHLORO-4-HYDROXYPHENYL)AMINO)-6-QUINAZOLINYL)-
WEAK INHIBITOR->TARGET
IC50
GP-2 HER2-DERIVED, HLA-A2+ RESTRICTED PEPTIDE
ANTIGEN->TARGET
ANBENITAMAB
INHIBITOR -> TARGET
Structure of PELITINIB
INHIBITOR -> TARGET
ZENOCUTUZUMAB
INHIBITOR -> TARGET
IgG1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity targeting HER2 and HER3 receptors.
Trastuzumab brengitecan
INHIBITOR -> TARGET
TEZATABEP MATRAXETAN
LIGAND->TARGET
DHES-0815A
CONJUGATED TOXIN->TARGET
ZANIDATAMAB
INHIBITOR -> TARGET
Structure of POZIOTINIB
INHIBITOR -> TARGET
PERTUZUMAB DEFEROXAMINE ZIRCONIUM ZR-89
RADIOLIGAND->TARGET
MM-111
LIGAND->TARGET
Structure of N-DESMETHYL NERATINIB
INHIBITOR -> TARGET
Structure of AV-412 FREE BASE
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
IC50
Trastuzumab Vedotin
CONJUGATED TOXIN->TARGET
MRG002 potently inhibited proliferation of HER2 expressing cancer cells in vitro with IC50 ranged from 1.8±0.8 to 59.9±8.9 ng/mL,
AV-203
INHIBITOR -> TARGET
Structure of SPH-5030
INHIBITOR -> TARGET
IC50
Structure of N-(4-((3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2,3-DIHYDROXYPROPANAMIDE
WEAK INHIBITOR->TARGET
IC50
Structure of MUBRITINIB
INHIBITOR -> TARGET
Structure of CANERTINIB
INHIBITOR -> TARGET
EP-2101 COMPONENT LYS-VAL-PHE-GLY-SER-LEU-ALA-PHE-VAL
VACCINE ANTIGEN->TARGET
Structure of (3R,4R)-4-AMINO-1-((4-((3-METHOXYPHENYL)AMINO)PYRROLO(2,1-F)(1,2,4)TRIAZIN-5-YL)METHYL)-3-PIPERIDINYL .BETA.-D-GLUCOPYRANOSIDURONIC ACID
INHIBITOR -> TARGET
IC50
Structure of NERATINIB
INHIBITOR -> TARGET
DISITAMAB VEDOTIN
CONJUGATED TOXIN->TARGET
TIMIGUTUZUMAB
INHIBITOR -> TARGET
Fencabtagene Autoleucel
CYTOTOXIC T-CELL->TARGET
Structure of Sacibertinib
INHIBITOR -> TARGET
Anvatabart Pactil
LIGAND->TARGET
EP-2101 COMPONENT LYS-VAL-PHE-GLY-SER-LEU-ALA-PHE-VAL
TARGET->VACCINE ANTIGEN
GBR-1302
LIGAND->TARGET
Structure of BMS-690514
INHIBITOR -> TARGET
IC50
Structure of PYROTINIB
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
IC50
PERTUZUMAB
INHIBITOR -> TARGET
HER dimerization inhibitor
BINDING
ETBX-021
ANTIGEN->TARGET
Identified as a definitive diagnostic marker, key driver and therapeutic target for chordoma, a malignant tumor that arises from remnant notochordal cells lodged in the vertebrae
TRASTUZUMAB DUOCARMAZINE
INHIBITOR -> TARGET
MEDI-4276
CONJUGATED TOXIN->TARGET
Structure of VARLITINIB
INHIBITOR -> TARGET
FIDASIMTAMAB
LIGAND->TARGET
Structure of NERATINIB DIMETHYLAMINE N-OXIDE
INHIBITOR -> TARGET
Structure of AEE-788
INHIBITOR -> TARGET
Structure of ALLITINIB
INHIBITOR -> TARGET
irreversible selective inhibitor
IRREVERSIBLE INHIBITOR
IC50
DISITAMAB
INHIBITOR -> TARGET
TRASTUZUMAB CORIXETAN THORIUM TH-227
RADIOLIGAND->TARGET
CINREBAFUSP ALFA
INHIBITOR -> TARGET
Anvatabart Opadotin
CONJUGATED TOXIN->TARGET
NELIPEPIMUT-S
ANTIGEN->TARGET
Structure of EPERTINIB
INHIBITOR -> TARGET
ZANIDATAMAB ZOVODOTIN
CONJUGATED TOXIN->TARGET
Structure of AFATINIB
INHIBITOR -> TARGET
ZIRCONIUM ZR-89 TRASTUZUMAB
RADIOLIGAND->TARGET
Structure of (3R,4R)-4-AMINO-1-((4-((4-HYDROXY-3-METHOXYPHENYL)AMINO)PYRROLO(2,1-F)(1,2,4)TRIAZIN-5-YL)METHYL)-3-PIPERIDINOL
INHIBITOR -> TARGET
BMS-690514 metabolite M2 showed HER2 inhibition similar to that of BMS-690514.
IC50
Structure of NERATINIB PYRIDINE N-OXIDE
INHIBITOR -> TARGET
FS-102
INHIBITOR -> TARGET
Structure of IBRUTINIB
INHIBITOR->OFF-TARGET
IC50
Structure of TUCATINIB
INHIBITOR -> TARGET
SELECTIVE
Ki
Structure of NEPTINIB
INHIBITOR -> TARGET
TRASTUZUMAB
INHIBITOR -> TARGET
LAPULEUCEL-T
VACCINE ANTIGEN->TARGET
Structure of SAPITINIB
INHIBITOR -> TARGET
COPRELOTAMAB
INHIBITOR -> TARGET
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966